PAlliative RAdioTherapy to Lung Cancer A Randomized Multicentre Phase III Study
- Sponsor
- University of Aarhus
- Study ID
- NCT03632603
- Phase
- PHASE3
- Status
- Unknown
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- No intervention — RADIATIONNo intervention during study period.
Study Details
The aim of this study is to examine if a shorter palliative radiotherapy fractionation scheme of 20 Gy / 4 F can reduce the early oesophageal toxicity compared to 30 Gy / 10 F in patients with lung cancer in performance status (PS) 0-2. Secondary aims are to examine the effect on lung cancer symptoms, quality of life (QoL) and survival. Furthermore, the investigators aim at standardizing the quality of palliative thoracic radiotherapy in all Danish centres at the highest technical level.
Key Dates
- Start date
- Nov 22, 2018
- Status verified
- May 2024
- Primary completion
- Aug 31, 2025
- Completion
- Aug 31, 2025
Study Design
- Enrollment
- 1,184 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Radiotherapy 20 Gy / 4 FRadiotherapy 20 Gy / 4 F
- Active Comparator: Radiotherapy 30 Gy/ 10 FRadiotherapy 30 Gy/ 10 F
Primary Outcome Measure
Early oesophagitis [ Time Frame: 2 weeks after completion of radiotherapy ]
Central Contacts
- Marianne Marquard Knap, PhD, MD0045 22985576
- Lone Hoffmann, PhD,0045 29939779
Related Studies
- Evaluation for NCI Surgery Branch Clinical Research ProtocolsRecruiting · National Cancer Institute (NCI) · Bethesda, Maryland
- Collection of Blood From Patients With CancerRecruiting · National Cancer Institute (NCI) · Bethesda, Maryland
- Detection of Genetic Markers of Lung CancerRecruiting · University of Pittsburgh · Pittsburgh, Pennsylvania
- Lung Cancer Biomarkers and ScreeningRecruiting · NYU Langone Health · New York, New York